More than a small adult brain: Lessons from chemotherapy-induced cognitive impairment for modelling paediatric brain

Maya R Davies1, Zarina Greenberg2, Dannis G van Vuurden3

  • 1School of Biomedicine, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia; Supportive Oncology Research Group, Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia.

PubMed

Insights

Pediatric cancer treatments can harm the developing brain due to its unique vulnerabilities. More age-specific research and models are crucial for understanding and mitigating neurocognitive side effects in children.

Area of Science:

  • Neuroscience
  • Developmental Biology
  • Pediatric Oncology

Background:

  • The developing pediatric brain exhibits high neuroplasticity but immature protective mechanisms, increasing vulnerability to neurotoxic insults.
  • Paediatric cancer treatments (surgery, radiation, chemotherapy) can cause significant neurocognitive symptoms in children.
  • Current preclinical research predominantly uses adult models, limiting understanding of age-specific treatment effects.

Conclusions:

  • Developing age-specific in vitro and in vivo pediatric disease models is essential.
  • This research is critical for advancing discovery and ensuring clinically translatable findings for children.
  • Addressing the unique neurodevelopmental context is key to mitigating long-term neurocognitive deficits in pediatric cancer survivors.